Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling. In January 2018 Selcia became part of Eurofins Pharma Discovery Services affording Selcia the capacity to deliver extensive and seamless solutions and services that span the whole spectrum of drug discovery.
Selcia Drug Discovery focusses on integrated small molecule drug discovery, with a strong track record of IP generation and preclinical candidate delivery for customers – 25 patents and 11 preclinical candidates generated. USPs are the medicinal chemistry of macrocycles, and a peptidyl prolyl isomerase (PPIase) screening platform.
Selcia radiolabelling specialises in 14C GMP radiolabelling, producing 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, IV microdosing, dermal penetration, regulatory and environmental fate studies.
Selcia also offers GLP NMR and mass spectrometry services to support regulatory submissions, and specialised purification capabilities from analytical (µg) to multi-100g scale.
Areas of Expertise:
• Medicinal chemistry: Tool compounds; peptides; macrocycles; natural product chemistry
• Biology: Assay development; ADME screens; PPIase profiling
• Disease expertise: Anti-infectives; inflammation; CNS; pain; metabolic; oncology & ophthalmology
• Target classes: GPCRs; ion channels; enzymes; protein-protein interactions
• 14C Custom Radiosynthesis
• GMP 14C Radiolabelled API for Clinical Trials
• GLP/GMP Analytics – GLP NMR
• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.
Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
Sphere Fluidics Ltd
Encapsulating Biology, Transforming Discovery. #SphereFluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.
Biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells
SQN Clinical is one of the largest specialist Biometrics CROs in Europe and is the preferred clinical development partner for many pharmaceutical, biotechnology and animal healthcare companies in the UK, Europe and the rest of world. We have a breadth of experience in many therapeutic areas as well as clinical development phases. Noted for our flexibility we support the diverse needs of large and small organisations alike but always provide the assurance that advice and services offered will always meet development and regulatory needs.
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facility in Nottingham, UK, housing nearly 300 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.
SYNthesis Med Chem
Established in 2007 and headquartered in Melbourne, SYNthesis med chem has grown to become one of the leading chemistry focused contract research organisations in the world. SYNthesis collaborates with organisations that require access to high quality compound synthesis and medicinal chemistry capabilities and expertise.
Custom synthesis projects include the synthesis of focused libraries, reference compounds, advanced intermediates (medium-large scale), final target compounds (small-medium scale) and hit expansion libraries. Our medicinal chemists have significant expertise in heterocyclic chemistry, peptide/cyclic-peptide & peptidomimetic chemistry (solution phase), nucleotide synthesis, natural products chemistry, SP3 carbon chemistry, asymmetric synthetic chemistry, metathesis, the resolution of enantiomers and chiral synthesis.
SYNthesis currently employs around 200 synthetic and medicinal chemists and in addition to our facilities in Australia, SYNthesis has labs/offices in Shanghai & Suzhou (China), San Francisco and at Alderley Park where our Global Business Development office is located.
Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide. Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York and London.
UK BioIndustry Association (BIA)
Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org
Vaccitech is a spin-out company from the University of Oxford’s Jenner institute, one of the oldest and most renowned vaccine research centres in the world.
The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. The company’s protected chimpanzee adenovirus technology is the best way to generate T-cell responses and thereby generate lasting cell-mediated immunity. The assets are already in the clinic with very promising initial results.
XenoGesis Ltd. is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.
It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive pre-clinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies. Specifically,XenoGesis can identify the potential 'winners' and 'losers' in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.
To read the latest XenoGesis newsletter CLICK HERE.